Irska - engleski - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - tacrolimus - ointment - other dermatological preparations; tacrolimus

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

veloxis pharmaceuticals, inc - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.75 mg - envarsus xr is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants [see clinical studies (14.1)]. envarsus xr is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants [see clinical studies (14.2)]. envarsus xr is contraindicated in patients with known hypersensitivity to tacrolimus. pregnancy exposure registry there is a pregnancy registry that monitors pregnancy outcomes in women exposed to envarsus xr during pregnancy. the transplantation pregnancy registry international (tpri) is a voluntary pregnancy exposure registry that monitors outcomes of pregnancy in female transplant recipients and those fathered by male transplant recipients exposed to immunosuppressants including tacrolimus. healthcare providers are encouraged to advise their patients to register by contacting the transplantation pregnancy registry

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

physicians total care, inc. - tacrolimus (unii: wm0haq4wnm) (tacrolimus - unii:wm0haq4wnm) - tacrolimus 1 mg in 1 g - protopic ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. protopic ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). protopic (tacrolimus) ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

leo pharma inc - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.3 mg in 1 g - protopic® ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. protopic® ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). protopic® ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tacrolimus monohydrate, quantity: 5.112 mg (equivalent: tacrolimus, qty 5 mg) - capsule, hard - excipient ingredients: hypromellose; lactose monohydrate; croscarmellose sodium; magnesium stearate; gelatin; purified water; sodium lauryl sulfate; brilliant blue fcf; phloxine b; titanium dioxide; quinoline yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; ethanol absolute - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tacrolimus monohydrate, quantity: 1.022 mg (equivalent: tacrolimus, qty 1 mg) - capsule, hard - excipient ingredients: hypromellose; lactose monohydrate; croscarmellose sodium; magnesium stearate; gelatin; purified water; sodium lauryl sulfate; brilliant blue fcf; iron oxide yellow; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; ethanol absolute - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tacrolimus monohydrate, quantity: 0.511 mg (equivalent: tacrolimus, qty 0.5 mg) - capsule, hard - excipient ingredients: hypromellose; lactose monohydrate; croscarmellose sodium; magnesium stearate; gelatin; purified water; sodium lauryl sulfate; brilliant blue fcf; allura red ac; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; ethanol absolute - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Izrael - engleski - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izrael - engleski - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

Izrael - engleski - Ministry of Health

astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.